ALGN vs IOVA
Align Technology vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | ALGN | IOVA |
|---|
| AI Score |
73
|
67
|
| Price |
$172.86
|
$6.49
|
| P/E Ratio |
30.03×
|
-9.27×
|
| ROE |
10.1%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
116.3%
|
| Debt / Equity |
0.03×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.1
|
79.2
|
| Beta |
1.653
|
0.701
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus IOVA.
ALGN leads by 6 points.
ALGN scores 73/100 (Buy) versus IOVA at 67/100 (Buy).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical